Compare TYRA & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | PRLB |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 2011 |
| Metric | TYRA | PRLB |
|---|---|---|
| Price | $26.04 | $89.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $47.50 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 630.1K | 174.2K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.56 |
| Revenue Next Year | N/A | $6.89 |
| P/E Ratio | ★ N/A | $125.23 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $45.10 |
| 52 Week High | $40.65 | $91.98 |
| Indicator | TYRA | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 66.62 |
| Support Level | $24.77 | $70.63 |
| Resistance Level | $32.82 | N/A |
| Average True Range (ATR) | 1.75 | 3.80 |
| MACD | -0.67 | 1.40 |
| Stochastic Oscillator | 7.53 | 86.56 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.